ZA201407532B - Therapeutic uses of fibroblast growthfactor 21 proteins - Google Patents
Therapeutic uses of fibroblast growthfactor 21 proteinsInfo
- Publication number
- ZA201407532B ZA201407532B ZA2014/07532A ZA201407532A ZA201407532B ZA 201407532 B ZA201407532 B ZA 201407532B ZA 2014/07532 A ZA2014/07532 A ZA 2014/07532A ZA 201407532 A ZA201407532 A ZA 201407532A ZA 201407532 B ZA201407532 B ZA 201407532B
- Authority
- ZA
- South Africa
- Prior art keywords
- proteins
- therapeutic uses
- growthfactor
- fibroblast
- fibroblast growthfactor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646974P | 2012-05-15 | 2012-05-15 | |
| US201361786939P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/040275 WO2013173158A1 (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201407532B true ZA201407532B (en) | 2016-05-25 |
Family
ID=48483225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/07532A ZA201407532B (en) | 2012-05-15 | 2014-10-16 | Therapeutic uses of fibroblast growthfactor 21 proteins |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150141335A1 (OSRAM) |
| EP (1) | EP2852398A1 (OSRAM) |
| JP (1) | JP2015522539A (OSRAM) |
| KR (1) | KR20150002801A (OSRAM) |
| CN (1) | CN104302311A (OSRAM) |
| AU (1) | AU2013263188A1 (OSRAM) |
| BR (1) | BR112014028413A2 (OSRAM) |
| CA (1) | CA2869320A1 (OSRAM) |
| CL (1) | CL2014002846A1 (OSRAM) |
| CO (1) | CO7131381A2 (OSRAM) |
| EA (1) | EA201491856A1 (OSRAM) |
| HK (1) | HK1202800A1 (OSRAM) |
| IL (1) | IL235482A0 (OSRAM) |
| MA (1) | MA37506B1 (OSRAM) |
| MX (1) | MX2014013913A (OSRAM) |
| PE (1) | PE20142432A1 (OSRAM) |
| PH (1) | PH12014502537A1 (OSRAM) |
| SG (1) | SG11201407655TA (OSRAM) |
| TN (1) | TN2014000409A1 (OSRAM) |
| WO (1) | WO2013173158A1 (OSRAM) |
| ZA (1) | ZA201407532B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016039339A1 (ja) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108324928B (zh) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子-5在促骨折愈合中的应用 |
| EP3935075A4 (en) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| KR20240034235A (ko) | 2021-07-14 | 2024-03-13 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 대사 장애를 위한 융합 폴리펩타이드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101476472B1 (ko) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
-
2013
- 2013-05-09 CA CA2869320A patent/CA2869320A1/en not_active Abandoned
- 2013-05-09 EA EA201491856A patent/EA201491856A1/ru unknown
- 2013-05-09 AU AU2013263188A patent/AU2013263188A1/en not_active Abandoned
- 2013-05-09 EP EP13724685.6A patent/EP2852398A1/en not_active Withdrawn
- 2013-05-09 CN CN201380025338.6A patent/CN104302311A/zh active Pending
- 2013-05-09 WO PCT/US2013/040275 patent/WO2013173158A1/en not_active Ceased
- 2013-05-09 HK HK15103356.5A patent/HK1202800A1/xx unknown
- 2013-05-09 MX MX2014013913A patent/MX2014013913A/es unknown
- 2013-05-09 SG SG11201407655TA patent/SG11201407655TA/en unknown
- 2013-05-09 MA MA37506A patent/MA37506B1/fr unknown
- 2013-05-09 US US14/399,037 patent/US20150141335A1/en not_active Abandoned
- 2013-05-09 PE PE2014001980A patent/PE20142432A1/es not_active Application Discontinuation
- 2013-05-09 KR KR1020147031701A patent/KR20150002801A/ko not_active Withdrawn
- 2013-05-09 BR BR112014028413A patent/BR112014028413A2/pt not_active IP Right Cessation
- 2013-05-09 JP JP2015512695A patent/JP2015522539A/ja not_active Withdrawn
-
2014
- 2014-09-30 TN TNP2014000409A patent/TN2014000409A1/fr unknown
- 2014-10-16 ZA ZA2014/07532A patent/ZA201407532B/en unknown
- 2014-10-22 CL CL2014002846A patent/CL2014002846A1/es unknown
- 2014-11-03 IL IL235482A patent/IL235482A0/en unknown
- 2014-11-14 CO CO14252512A patent/CO7131381A2/es unknown
- 2014-11-14 PH PH12014502537A patent/PH12014502537A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2869320A1 (en) | 2013-11-21 |
| MX2014013913A (es) | 2015-02-17 |
| JP2015522539A (ja) | 2015-08-06 |
| US20150141335A1 (en) | 2015-05-21 |
| CL2014002846A1 (es) | 2015-01-30 |
| PE20142432A1 (es) | 2015-01-22 |
| TN2014000409A1 (en) | 2015-12-21 |
| PH12014502537A1 (en) | 2015-01-21 |
| SG11201407655TA (en) | 2014-12-30 |
| EA201491856A1 (ru) | 2015-03-31 |
| AU2013263188A1 (en) | 2014-10-16 |
| MA37506B1 (fr) | 2017-03-31 |
| CN104302311A (zh) | 2015-01-21 |
| MA37506A1 (fr) | 2016-01-29 |
| KR20150002801A (ko) | 2015-01-07 |
| WO2013173158A1 (en) | 2013-11-21 |
| BR112014028413A2 (pt) | 2017-11-07 |
| CO7131381A2 (es) | 2014-12-01 |
| HK1202800A1 (en) | 2015-10-09 |
| IL235482A0 (en) | 2014-12-31 |
| EP2852398A1 (en) | 2015-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262600A (en) | Vectors and their medical uses | |
| IL235482A0 (en) | Medical uses of fibroblast growth factor 21 proteins | |
| IL233756A0 (en) | New treatment factors | |
| GB201212513D0 (en) | Therapeutic agents | |
| IL279676A (en) | Recombinant proteins and therapeutic uses | |
| ZA201405627B (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| IL236616A0 (en) | 5-aminotetrahydroquinoline-2-new carboxylic acids and their use | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
| EP2850093A4 (en) | THERAPEUTIC IL-13 POLYPEPTIDES | |
| GB201217704D0 (en) | Therapeutic agents | |
| GB201420971D0 (en) | Therapeutic composition | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| EP2804853A4 (en) | THERAPEUTIC USES | |
| SI2555790T1 (sl) | Terapevtska uporaba proteina beta2-mikroglobulina | |
| GB201207907D0 (en) | Treatment of depression | |
| GB201214985D0 (en) | Modified therapeutic agents | |
| GB201213712D0 (en) | Modified therapeutic agents | |
| ZA201405764B (en) | Novel therapeutic agents | |
| GB201223021D0 (en) | Therapeutic agents | |
| GB201212512D0 (en) | Therapeutic agents | |
| GB201210233D0 (en) | Therapeutic agents | |
| GB201202596D0 (en) | Therapeutic uses of flavin-containing monooxygenase 3 | |
| AP2015008228A0 (en) | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |